01/17/2025
8:15 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
8:16 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
8:17 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
8:17 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/17/2025
2:07 PM | Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025
1:42 PM | Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025
1:50 PM | Adaptimmune Therapeutics (Subject)
Bertrand William C JR (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2025
1:59 PM | Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
3:15 PM | Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:16 PM | Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:17 PM | Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for ADAP and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
01/15/2025
3:18 PM | Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
3:19 PM | Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/15/2025
2:43 PM | Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
2:50 PM | Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
2:34 PM | Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2025
9:30 AM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
12/19/2024
6:40 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
4:17 PM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SCHEDULE 13G/A | |
11/13/2024
8:04 AM | Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
8:10 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
4:00 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/23/2024
3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/12/2024
6:23 AM | Adaptimmune Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/12/2024
6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/02/2024
6:00 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/16/2024
3:30 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:39 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:14 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2024
6:34 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/22/2024
4:15 PM | Adaptimmune Therapeutics (Filer)
| Form ARS | |
04/12/2024
7:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/11/2024
7:00 AM | Adaptimmune Therapeutics (Filer)
| Form DEF 14A | |
04/02/2024
7:38 PM | Adaptimmune Therapeutics (Subject)
New Enterprise Associates 14, L.P. (Filed by)
| Form SC 13D/A | |
04/01/2024
7:01 AM | Adaptimmune Therapeutics (Filer)
| Form PRE 14A | |
03/26/2024
10:59 AM | Adaptimmune Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SC 13G/A | |
03/26/2024
11:00 AM | Adaptimmune Therapeutics (Issuer)
EcoR1 Capital, LLC (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/06/2024
6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/06/2024
6:12 AM | Adaptimmune Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/27/2024
7:13 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/31/2024
4:07 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Is this Elon’s true agenda? (Ad) All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell them Click here for my report |
